ARQT vs. OPK, SPRY, ABVX, OCUL, IMNM, PRAX, ETNB, TYRA, ALXO, and SAVA
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include OPKO Health (OPK), ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), Immunome (IMNM), Praxis Precision Medicines (PRAX), 89bio (ETNB), Tyra Biosciences (TYRA), ALX Oncology (ALXO), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
OPKO Health presently has a consensus target price of $3.17, indicating a potential upside of 134.57%. Arcutis Biotherapeutics has a consensus target price of $27.00, indicating a potential upside of 192.21%. Given OPKO Health's higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than OPKO Health.
64.6% of OPKO Health shares are held by institutional investors. 47.3% of OPKO Health shares are held by company insiders. Comparatively, 20.7% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
OPKO Health has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
OPKO Health received 444 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 65.87% of users gave OPKO Health an outperform vote while only 62.07% of users gave Arcutis Biotherapeutics an outperform vote.
In the previous week, Arcutis Biotherapeutics had 14 more articles in the media than OPKO Health. MarketBeat recorded 25 mentions for Arcutis Biotherapeutics and 11 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.81 beat Arcutis Biotherapeutics' score of -0.15 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
OPKO Health has a net margin of -31.44% compared to OPKO Health's net margin of -439.79%. Arcutis Biotherapeutics' return on equity of -17.89% beat OPKO Health's return on equity.
OPKO Health has higher revenue and earnings than Arcutis Biotherapeutics. OPKO Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
OPKO Health beats Arcutis Biotherapeutics on 12 of the 18 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
